Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer

A Phase II Trial of Erlotinib in Combination With Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer

The purpose of this study is to determine the response rate of gemcitabine, cisplatin and erlotinib in metastatic pancreatic cancer.

Inclusion Criteria:

• Age older than 18
• Younger than 75
• ECOG performance status 0 or 1
• Histologically confirmed adenocarcinoma of the pancreas
• Metastatic pancreatic cancer
• No prior chemotherapy for metastatic pancreatic cancer
• A patient with at least one measurable primary lesion of which the diameter is confirmed to be 10mm in Spiral CT or multidetector CT (MD CT)

Exclusion Criteria:

• A patient with no measurable disease
• A patient who received previous palliative chemotherapy for pancreatic cancer
• A patient with locally advanced pancreatic cancer
• A patient who received adjuvant chemotherapy for pancreatic cancer within 1 year
• A patient with previous active or passive immunotherapy
• A pregnant or lactating patient